Research suggests no difference in morning versus evening dosing for warfarin

February 18, 2020

Patients taking warfarin to reduce the risk of stroke and pulmonary embolisms are often advised to take the medication in the evening. But does time of day really matter? A new study shows evidence that morning versus evening dosing has insignificant bearing on how long the drug provides the most benefit for preventing adverse health events. Two hundred and seventeen adults who regularly used warfarin in the evenings were randomized to the trial, with about half switching to morning medication use for seven months. Researchers measured the effectiveness of the drug by tracking the proportion of time that patients spent outside of the range for maximum effectiveness of the drug. Therapeutic changes did not significantly differ for patients who switched to morning administration. The clinical research team concluded that the time of day a patient takes the medicine has no effect on the stability of warfarin's anticoagulant effect. Patients should take warfarin whenever regular compliance would be easiest.
-end-
The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial
Scott R. Garrison MD, PhD, et al
University of Alberta, Department of Family Medicine, Edmonton, Alberta, Canada
http://www.annfammed.org/content/18/1/42

American Academy of Family Physicians

Related Warfarin Articles from Brightsurf:

Rivaroxaban may be as effective as warfarin for bioprosthetic mitral valves, AF
The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm.

Warfarin use significantly increases risk of knee and hip replacement in people with OA
New research shows that use of warfarin is associated with a significantly greater risk of knee and hip replacements in patients with OA.

AMP recommends minimum set of pharmacogenetic alleles to help standardize clinical genotyping testing for warfarin response
AMP has published consensus, evidence-based recommendations to aid in the design, validation and interpretation of clinical genotyping tests for the prediction of warfarin response.

Research suggests no difference in morning versus evening dosing for warfarin
Patients taking warfarin to reduce the risk of stroke and pulmonary embolisms are often advised to take the medication in the evening.

Eating more vitamin K found to help, not harm, patients on warfarin
When prescribed the anticoagulant drug warfarin, many patients are told to limit foods rich in vitamin K, such as green vegetables.

New anti-clotting drugs linked to lower risk of serious bleeding
New drugs known as direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

Researchers lengthen intervals between blood draws for warfarin patients
A new study finds stable patients on blood thinners may not need to get their blood drawn as often as they currently do.

Herbal products may compromise prescription drugs and cause serious side effects
An analysis of published studies and reports indicates that a number of herbal products may affect the properties of prescription drugs, leading to alterations in the drugs' effectiveness as well as potentially dangerous side effects.

Is anticoagulant warfarin associated with lower risk of cancer incidence?
Bottom Line: Use of the blood thinner warfarin was associated with a lower risk of new cancers in people over 50.

New anti-clotting drugs not associated with higher risk of major bleeding
A new group of drugs used to treat patients with serious blood clots are not associated with a higher risk of major bleeding compared with the older anti-clotting drug, warfarin, finds a study published by The BMJ today.

Read More: Warfarin News and Warfarin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.